Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.36 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
| ▸ | TOP1 | P11387 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2316246 | 1.00 | LMNA (0.46) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL33584 | 1.00 | LMNA (0.46) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL3130561 | 1.00 | LMNA (0.46) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL4126076 | 1.00 | LMNA (0.46) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL3128140 | 1.00 | LMNA (0.46) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL342904 | 1.00 | LMNA (0.46) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Ammonia Solution, Strong SCHEMBL16720911 | 0.98 | LMNA (0.44) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL8675811 | 0.98 | TDP1 (0.48) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Acetic Acid SCHEMBL680584 | 0.94 | PDE4A (0.44) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL616881 | 0.94 | LMNA (0.42) | LMNAL3MBTL1TDP1KDM4EPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110226640-A | A kind of full nutrient formulation powder and its manufacturing method | 宁波特壹食品有限公司 | 2019-09-13 | — | — | CN | claimed |
| CN-109172627-A | The preparation method of cactus fine powder | 健掌（上海）生物科技有限公司 | 2019-01-11 | — | — | CN | claimed |
| US-9181536-B2 | Method for preparing immobilized angiogenin | NAIDU LP (US) | 2015-11-10 | — | — | US | claimed |
| US-20150265701-A1 | IMMUNOMODULATING COMPOSITIONS AND USES THEREFOR | CANCURE LIMITED ACN 164 438 359 (AU) | 2015-09-24 | — | — | US | claimed |
| US-20150010979-A1 | METHOD FOR PREPARING IMMOBILIZED ANGIOGENIN | NAIDU LP | 2015-01-08 | — | — | US | claimed |
| US-8828698-B2 | Immobilized angiogenin mixtures and uses thereof | NAIDU LP (US) | 2014-09-09 | — | — | US | claimed |
| US-20080254018-A1 | Solid support comprising stably conjugated neovascularizing protein for use in identifying modulators of cell proliferation | NAIDU LP | 2008-10-16 | — | — | US | claimed |
| US-20070207161-A1 | Immunomodulating Compositions and uses Therefor | CANCURE LIMITED ACN 164 438 359 (AU) | 2007-09-06 | — | — | US | claimed |
| JP-2007508328-A | — | — | 2007-04-05 | — | — | JP | claimed |
| EP-1682159-A1 | IMMUNOMODULATING COMPOSITIONS AND USES THEREFOR | Ralph, John Stephen (AU) | 2006-07-26 | — | — | EP | claimed |
| WO-2005037293-A1 | IMMUNOMODULATING COMPOSITIONS AND USES THEREFOR | UNIV MONASH (AU) | 2005-04-28 | — | — | WO | claimed |
| EP-1259619-A2 | VARIANT GALACTOSE OXIDASE, NUCLEIC ACID ENCODING SAME, AND METHODS OF USING SAME | HERCULES INCORPORATED (US) | 2002-11-27 | — | — | EP | claimed |
| WO-2001062938-A2 | VARIANT GALACTOSE OXIDASE, NUCLEIC ACID ENCODING SAME, AND METHODS OF USING SAME | HERCULES INCORPORATED (US) | 2001-08-30 | — | — | WO | claimed |
| US-20260026508-A1 | Seed Treatment Formulations and Methods of Use | PUNA BIO CORP (US) | 2026-01-29 | — | — | US | disclosed |
| EP-4605371-A1 | POLYOL-DERIVED COMPOUNDS | Arxada AG (CH) | 2025-08-27 | — | — | EP | disclosed |
| US-20250011265-A1 | COMPOSITIONS AND METHODS FOR PRODUCTION OF ANTIMICROBIAL AGENTS FROM BIO-RENEWABLE FEEDSTOCKS | SOLUGEN, INC. (US) | 2025-01-09 | — | — | US | disclosed |
| WO-1994018340-A1 | ALTEROMONAS-TYPE BACTERIA, POLYSACCHARIDES PRODUCED BY SAID BACTERIA, OSE CONTAINED IN SAID POLYSACCHARIDES AND APPLICATIONS | INSTITUT FRANÇAIS DE RECHERCHE POUR L'EXPLOITATION DE LA MER - IFREMER (FR) | 1994-08-18 | — | — | WO | disclosed |
| EP-0586687-A1 | TRANS-SIALIDASE AND METHODS OF USE AND MAKING THEREOF | NEW YORK UNIVERSITY (US) | 1994-03-16 | — | — | EP | disclosed |
| WO-1993018787-A1 | TRANS-SIALIDASE AND METHODS OF USE AND MAKING THEREOF | NEW YORK UNIVERSITY (US) | 1993-09-30 | — | — | WO | disclosed |
| EP-0033433-A1 | Macrolide antibiotics, process for their preparation, inter alia by fermentation, and pharmaceutical compositions containing them | SCHERING CORPORATION (US) | 1981-08-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260026508-A1 | Seed Treatment Formulations and Methods of Use | PGLS, GNE, GALE | LMNA 2892/4885L3MBTL1 3800/4885TDP1 2736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.